Marksans Pharma Arm Relonchem Bags UK MHRA Marketing Nod For Oral Solution To Treat Epilepsy
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Levetiracetam Relonchem 100 mg/mL Oral Solution from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (UK MHRA).
Levetiracetam, a medication used for the treatment of epilepsy, helps in managing specific seizure types.
The product will be manufactured at the Group’s UK manufacturing facility.
Read also: Marksans Pharma bags USFDA nod for Esomeprazole Magnesium Delayed Release Capsules
Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.
Read also: Marksans Pharma arm gets marketing authorisation for Cyanocobalamin 50mg film coated tablets from UK MHRA
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!